Six-hour DMT infusion studied in healthy volunteers

Weiße, nadelförmige DMT-Kristalle in sternförmigen Büscheln am Boden eines Glasgefäßes.

Translated from our German original by AI. The German text was researched, written, and edited by the Psychedelia Foundation team and remains the authoritative version.

A randomized, double-blind, placebo-controlled study in 29 healthy adults examined the safety, pharmacokinetics, and pharmacodynamic effects of a six-hour intravenous infusion of N,N-dimethyltryptamine (DMT). At the highest dose, mild psychedelic effects occurred, along with measurable changes in attention, postural stability, and EEG alpha activity.

Participants received either DMT or placebo. DMT was first given as an intravenous bolus over 30 seconds, followed by a six-hour infusion. Three dose levels were tested. At the highest dose, the mean peak DMT plasma concentration was about 36 nanograms per milliliter.

No serious adverse events or clinically significant ECG abnormalities were found. The most common side effects included headache, nausea, and fatigue. The highest dose also brought a temporary rise in systolic blood pressure and dilated pupils. One person developed anxiety after the middle dose that required psychological counseling and lasted for several months. This case tempers the otherwise favorable picture of tolerability.

At higher doses, the neurophysiological tests showed more body sway and poorer results on a task measuring sustained attention and visuomotor skills. EEG alpha activity decreased over parieto-occipital brain regions. No changes were found in blood levels of BDNF.

The research relates to preclinical findings suggesting that DMT could influence neuroplastic processes and, in animal models, improve recovery after ischemic stroke. The present study, however, included no stroke patients and did not measure neuroplasticity or functional rehabilitation as clinical endpoints. It therefore provides no evidence that DMT works as a treatment after a stroke.

The findings are limited by the small sample and the selection of healthy participants. DMT plasma concentrations also varied considerably from person to person. The authors see the results as a basis for further mechanistic studies in patient groups.

Source

van Der Heijden, K. V., Zuiker, R. G., Otto, M. E., Bryan, C. S., Stewart, N., Stillwell, C. et al. (2025), Safety, pharmacokinetics, and pharmacodynamics of a 6‐h N, N‐dimethyltryptamine (DMT) infusion in healthy volunteers: a randomized, double‐blind, placebo‐controlled trial, Clinical and Translational Science 18(5): e70234.

Read the study, opens in a new tab ascpt.onlinelibrary.wiley.com

Share

Newsletter - Subscribe to our newsletter to get insights into current projects and events.

Stay connected with a community that fosters a responsible and forward-thinking dialogue on psychedelic experience – and receive news about projects, events, and publications.